Form Type and Filing Date: This is a Form 8-K Current Report filed by Cardinal Health, Inc. on January 13, 2026, reporting events as of that same date. Items Being Reported: The filing indicates two items are included - Item 5.02 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), though the specific details of these disclosures are not fully visible in the provided…

Our analysis rates this filing NEUTRAL. Cardinal Health presents a balanced risk-reward profile warranting MODERATE concern assessment. Positive factors substantially outweigh concerns: the company has raised guidance twice consecutively, successfully navigated complex IRA regulatory changes, and…

Concern level: ELEVATED (5.2/10). Key factors: DOJ investigations into Anti-Kickback Statute and False Claims Act violations represent material legal/financial contingent liability with unquantified exposure; Ongoing regulatory uncertainty regarding IRA Medicare Drug Price Negotiation Program implementation and potential future margin compression from pricing changes; Forward-looking statements…

Notable risk changes: POSITIVE: FY2026 Non-GAAP EPS guidance raised to 'at least $10.00' from prior range of $9.65-$9.85 (3.6% increase at midpoint), demonstrating strong operational performance and execution; POSITIVE: Specialty segment revenues expected to exceed $50 billion in FY2026 with 16% CAGR over three years, driven by robust specialty distribution demand, MSO platform expansion, and 30%+ BioPharma…

No earnings surprise data disclosed in this 8-K filing.

The model predicts CAH will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.